Terms: = Skin cancer AND TRIM33, RFG7, 51592, ENSG00000197323, Q9UPN9, TF1G, FLJ32925, TIF1G, PTC7, TIFGAMMA, TIF1GAMMA
25 results:
1. Paraneoplastic myopathies.
Mammen AL
Handb Clin Neurol; 2024; 200():327-332. PubMed ID: 38494286
[TBL] [Abstract] [Full Text] [Related]
2. TIF1γ and SMAD4 regulation in colorectal cancer: impact on cell proliferation and liver metastasis.
Wu Y; Yu B; Ai X; Zhang W; Chen W; Laurence A; Zhang M; Chen Q; Shao Y; Zhang B
Biol Chem; 2024 Apr; 405(4):241-256. PubMed ID: 38270141
[TBL] [Abstract] [Full Text] [Related]
3. Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti-Transcriptional Intermediary Factor 1γ Juvenile-Onset Dermatomyositis.
Sherman MA; Yang Q; Gutierrez-Alamillo L; Pak K; Flegel WA; Mammen AL; Rider LG; Casciola-Rosen LA;
Arthritis Rheumatol; 2024 Apr; 76(4):631-637. PubMed ID: 38059274
[TBL] [Abstract] [Full Text] [Related]
4. Clinical features of dermatomyositis patients with anti-TIF1 antibodies: A case based comprehensive review.
Kilinc OC; Ugurlu S
Autoimmun Rev; 2023 Dec; 22(12):103464. PubMed ID: 37863375
[TBL] [Abstract] [Full Text] [Related]
5. Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature.
Guerra NL; Matas-García A; Serra-García L; Morgado-Carrasco D; Padrosa J; Aldecoa I; Duque Y; Casal-Dominguez M; Muñoz-Braceras S; Aranega R; Moreno-Lozano P; Cantó-Santos J; Garrabou G; Ruiz-Ortiz E; Trallero-Araguas E; Selva-O'Callaghan A; Grau JM; Puig S; Torres-Ruiz J; Mammen AL; Fernandez IP; Milisenda JC
Autoimmun Rev; 2023 Aug; 22(8):103375. PubMed ID: 37321468
[TBL] [Abstract] [Full Text] [Related]
6. Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis.
Pinal-Fernandez I; Quintana A; Milisenda JC; Casal-Dominguez M; Muñoz-Braceras S; Derfoul A; Torres-Ruiz J; Pak K; Dell'Orso S; Naz F; Gutierrez-Cruz G; Milone M; Shelly S; Duque-Jaimez Y; Tobias-Baraja E; Matas-Garcia A; Garrabou G; Padrosa J; Ros J; Trallero-Araguás E; Walitt B; Christopher-Stine L; Lloyd TE; Zhao C; Swift S; Rajan A; Grau-Junyent JM; Selva-O'Callaghan A; Liewluck T; Mammen AL
Ann Rheum Dis; 2023 Jun; 82(6):829-836. PubMed ID: 36801811
[TBL] [Abstract] [Full Text] [Related]
7. Association of Anti-CCAR1 Autoantibodies With Decreased cancer Risk Relative to the General Population in Patients With Anti-Transcriptional Intermediary Factor 1γ-Positive Dermatomyositis.
Fiorentino D; Mecoli CA; Igusa T; Albayda J; Paik JJ; Tiniakou E; Adler B; Mammen AL; Shah AA; Rosen A; Christopher-Stine L; Casciola-Rosen L
Arthritis Rheumatol; 2023 Jul; 75(7):1238-1245. PubMed ID: 36762496
[TBL] [Abstract] [Full Text] [Related]
8. Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies.
Hosono Y; Sie B; Pinal-Fernandez I; Pak K; Mecoli CA; Casal-Dominguez M; Warner BM; Kaplan MJ; Albayda J; Danoff S; Lloyd TE; Paik JJ; Tiniakou E; Aggarwal R; Oddis CV; Moghadam-Kia S; Carmona-Rivera C; Milisenda JC; Grau-Junyent JM; Selva-O'Callaghan A; Christopher-Stine L; Larman HB; Mammen AL
Ann Rheum Dis; 2023 Feb; 82(2):246-252. PubMed ID: 36008132
[TBL] [Abstract] [Full Text] [Related]
9. Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis: A case report.
Kim Y; Park D; Choi SY; Chung C
Thorac Cancer; 2022 Oct; 13(19):2808-2811. PubMed ID: 35982637
[TBL] [Abstract] [Full Text] [Related]
10. Subsets of Idiopathic Inflammatory Myositis Enriched for Contemporaneous cancer Relative to the General Population.
Mecoli CA; Igusa T; Chen M; Wang X; Albayda J; Paik JJ; Tiniakou E; Adler B; Richardson C; Kelly W; Danoff S; Mammen AL; Platz EA; Rosen A; Christopher-Stine L; Casciola-Rosen L; Shah AA
Arthritis Rheumatol; 2023 Apr; 75(4):620-629. PubMed ID: 35878018
[TBL] [Abstract] [Full Text] [Related]
11. Paraneoplastic Wong-Type Dermatomyositis Associated with Gynecological Malignancy.
Russo R; Gasparini G; Cozzani E; Gravina B; Parodi A
Medicina (Kaunas); 2022 Mar; 58(4):. PubMed ID: 35454323
[TBL] [Abstract] [Full Text] [Related]
12. Anti-Mi-2 and Anti-TIF1-γ Double-Positive Juvenile Dermatomyositis Treated under Diagnosis of Chronic Eczema: A Case Report.
Yoshida S; Matsumoto H; Fujita Y; Yokose K; Temmoku J; Matsuoka N; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Yago T; Yaguchi T; Aita T; Kusano M; Yamamoto T; Watanabe H; Migita K
Tohoku J Exp Med; 2022 Apr; 256(4):303-308. PubMed ID: 35296571
[TBL] [Abstract] [Full Text] [Related]
13. Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1γ antibodies.
Ly NTM; Ma N; Ueda-Hayakawa I; Nguyen CTH; Anada R; Okamoto H; Fujimoto M
J Dermatol Sci; 2021 Dec; 104(3):177-184. PubMed ID: 34772582
[TBL] [Abstract] [Full Text] [Related]
14. A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast cancer.
Piras M; Panebianco M; Garibaldi M; Roberto M; Merlonghi G; Pellegrini P; Marchetti P
Curr Oncol; 2021 May; 28(3):1957-1961. PubMed ID: 34073827
[TBL] [Abstract] [Full Text] [Related]
15. NanoString technology distinguishes anti-TIF-1γ
Preusse C; Eede P; Heinzeling L; Freitag K; Koll R; Froehlich W; Schneider U; Allenbach Y; Benveniste O; Schänzer A; Goebel HH; Stenzel W; Radke J
Brain Pathol; 2021 May; 31(3):e12957. PubMed ID: 34043263
[TBL] [Abstract] [Full Text] [Related]
16. trim33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1γ positive cancer-associated dermatomyositis.
Cordel N; Derambure C; Coutant S; Mariette X; Jullien D; Debarbieux S; Chosidow O; Meyer A; Bessis D; Joly P; Mathian A; Levesque H; Sabourin JC; Tournier I; Boyer O;
Rheumatology (Oxford); 2021 Dec; 60(12):5863-5867. PubMed ID: 33764396
[TBL] [Abstract] [Full Text] [Related]
17. Presence of anti-transcriptional intermediary factor-1 gamma antibodies in a dermatomyositis patient with retroperitoneal cancer of unknown primary site.
Hori H; Ozeki Y; Kobashigawa T; Futsuhara K; Tanaka A; Watanabe E; Yabe H; Yago T; Fukuchi T; Sugawara H; Kotake S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):62-68. PubMed ID: 33269651
[TBL] [Abstract] [Full Text] [Related]
18. Anti-TIF1-γ autoantibodies: warning lights of a tumour autoantigen.
De Vooght J; Vulsteke JB; De Haes P; Bossuyt X; Lories R; De Langhe E
Rheumatology (Oxford); 2020 Mar; 59(3):469-477. PubMed ID: 31883334
[TBL] [Abstract] [Full Text] [Related]
19. Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis.
Wolstencroft PW; Casciola-Rosen L; Fiorentino DF
JAMA Dermatol; 2018 Oct; 154(10):1199-1203. PubMed ID: 30140893
[TBL] [Abstract] [Full Text] [Related]
20. Autoantibody to transcriptional intermediary factor-1β as a myositis-specific antibody: clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy.
Ueda-Hayakawa I; Hamaguchi Y; Okiyama N; Motegi S; Yamaoka T; Miyake S; Higashi A; Okamoto H; Takehara K; Fujimoto M
Br J Dermatol; 2019 Apr; 180(4):881-887. PubMed ID: 30120913
[TBL] [Abstract] [Full Text] [Related]
[Next]
